News 
Contact Us
No. 18, Fuyuan Road, Tianjin Wuqing Development Area, China
Deepening International Cooperation in Biomedicine! Swiss Innovation China Roadshow Successfully Held in Wuqing
On the afternoon of March 13th, the Wuqing Development Area, in collaboration with Succeed Consulting and Panshi Capital, hosted the Swiss Innovation China Roadshow. The Swiss Biomedical Delegation to China gathered with representatives from over 10 park enterprises, including Huasheng Biology, Tsingke Biotechnology, Junke Zhengyuan, Novogene, and BMC Medical, as well as representatives from investment institutions such as Botong Venture Capital, Haichuang Yifu, Zhongkeda, and the Tianjin OTC Exchange. They came together for a Sino-Swiss science and innovation event, exploring new opportunities for collaboration in the biomedical industry.
Leveraging resources from top-tier academic institutions like ETH Zurich and EPFL, and connecting with innovation hubs such as technology parks and incubators, Succeed Consulting has amassed a wealth of high-quality innovation project resources and high-end entrepreneurial talent. It serves as a vital bridge connecting the European tech ecosystem with the Chinese market. In December 2025, Succeed Consulting, in partnership with Panshi Capital and Technopark, successfully held the first roadshow in Wuqing, precisely selecting high-quality projects in areas like medical devices. This established a professional platform for high-level dialogue and cooperation between the Sino-Swiss biomedical industries, contributing to the high-quality development of Wuqing's biomedical sector. This roadshow marked the second major collaborative event, coinciding with the inaugural year of the "15th Five-Year Plan." Its success inaugurated a new journey for Wuqing District in attracting investment and fostering collaboration with Swiss science and innovation projects.
At the event, the Swiss Biomedical Delegation to China showcased 21 biomedical projects spanning cutting-edge technology, clinical application, and market translation. The technological focus covered multiple fields, including regenerative medicine, precision aesthetics, and oncology drug development, fully demonstrating Switzerland's top-tier innovation strength in the life sciences.
Beat Schillig, Swiss Biomedical Delegation to China
"AdiPearl is the world's first injectable biomaterial that induces adipogenesis (fat generation) through physical means. It can be applied in dermatology, plastic and reconstructive surgery. A single injection activates the body's own biological mechanisms to regenerate active, vascularized adipose tissue. We are very optimistic about the industrial foundation and development environment of Wuqing Development Area and eagerly look forward to engaging in deep cooperation with local enterprises and medical institutions in Wuqing to achieve technological implementation and mutual market success."
Yves Dudal, Swiss Biomedical Delegation to China
"PERSEO PHARMA possesses a mucoadhesive shielding therapeutic enzyme platform for metabolic disease treatment. Its proprietary nanoparticle shell anchors the enzyme to the intestinal mucosa, extending its retention time threefold. We sincerely hope to find quality partners in Wuqing. Relying on Wuqing's excellent industrial ecosystem and business environment, we aim to facilitate the local translation and implementation of our cutting-edge research achievements and jointly explore the Chinese market."
Jens Michael Kelm, Swiss Biomedical Delegation to China
"PreComb Therapeutics AG has developed an AI-driven organoid high-throughput screening platform that combines image analysis with drug efficacy assessment. The technology covers drug development for common cancers and various rare diseases, providing efficient and precise core support for innovative drug discovery. We hope to leverage this roadshow as an opportunity to reach cooperation agreements with biomedical companies and investment institutions in Wuqing, jointly promoting the implementation of cutting-edge technologies and contributing to the high-quality development of the regional pharmaceutical innovation industry."
Representatives from the attending park enterprises and investment institutions engaged in in-depth discussions and matchmaking with the Swiss Biomedical Delegation on core topics such as technology translation, market implementation, industrial supporting facilities, and collaboration models. The on-site interactions were lively, resulting in several preliminary cooperation intentions and laying a solid foundation for the subsequent implementation and translation of projects.
Wang Jibin, Party Secretary and Chairman of the Board of Wuqing Development Area Co., Ltd., stated, "This event has further deepened the collaborative link between Wuqing Development Area and Swiss science and innovation resources, building an important bridge for introducing international top-tier technologies and gathering high-end innovation elements into the regional biomedical industry. We sincerely welcome Swiss entrepreneurs and research teams to visit, invest in, and establish themselves in Wuqing, deepening technological connections, project implementation, and achievement translation, and working together to create a model of transnational industrial synergy and win-win innovation. Wuqing Development Area will continue to focus on the biomedical industry as a leading sector, centering on creating a world-class business environment. We will strengthen full-process service guarantees, precisely connect with top-tier global innovation resources from Switzerland and beyond, and accelerate the implementation and translation of quality science and innovation projects, high-end talent, and high-quality capital. By empowering high-quality development with high-standard opening-up, we aim to get the '15th Five-Year Plan' off to a strong start and strive to write a new chapter in the region's industrial innovation and development."
Source：Wuqing Development Area
Release Time：2026-03-13 21:06:20
Home